2812 related articles for article (PubMed ID: 7640041)
1. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients.
Gold JE; Ross SD; Krellenstein DJ; LaRosa F; Malamud SC; Osband ME
Eur J Cancer; 1995; 31A(5):698-708. PubMed ID: 7640041
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
3. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
4. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
5. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
6. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
Gold JE; Masters TR; Osband ME
J Surg Res; 1995 Aug; 59(2):279-86. PubMed ID: 7543632
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Bloom ND; Shafir MK; Klein MJ; Kenan S; Osband ME
J Surg Oncol; 1995 Apr; 58(4):212-21. PubMed ID: 7723363
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Babbit B; Fine EM; Weber HN; Unger PD; Leventhal I; Zippe CD; Osband ME
Br J Urol; 1995 Jul; 76(1):115-22. PubMed ID: 7648042
[TBL] [Abstract][Full Text] [Related]
9. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.
Gold JE; Malamud SC; LaRosa F; Osband ME
Am J Hematol; 1993 Sep; 44(1):42-7. PubMed ID: 8342564
[TBL] [Abstract][Full Text] [Related]
10. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Bleiweiss IJ; Goldfarb AB; Bauer JJ; Gelernt IM; Schwartz ME; Reiner MA; Miller CM; Weiss MF; Brower ST
J Surg Oncol; 1994 Apr; 55(4):222-8. PubMed ID: 8159004
[TBL] [Abstract][Full Text] [Related]
11. Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide.
Gold JE; Malamud SC; LaRosa F; Seder R; Osband ME
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):213-21. PubMed ID: 8471596
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
14. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
Curti BD; Ochoa AC; Powers GC; Kopp WC; Alvord WG; Janik JE; Gause BL; Dunn B; Kopreski MS; Fenton R; Zea A; Dansky-Ullmann C; Strobl S; Harvey L; Nelson E; Sznol M; Longo DL
J Clin Oncol; 1998 Aug; 16(8):2752-60. PubMed ID: 9704728
[TBL] [Abstract][Full Text] [Related]
16. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A; Lev-Ari S; Meirson T; Jacoby E; Asher N; Ben-Betzalel G; Itzhaki O; Shapira-Frommer R; Schachter J; Markel G; Besser MJ
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33990415
[TBL] [Abstract][Full Text] [Related]
17. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).
Masucci G; Svensson A; Hansson M; Hansson J; Nakazawa T; Salazar F; Petersson M; Kiessling R
J Hematother; 1997 Jun; 6(3):253-60. PubMed ID: 9234180
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
Schultze JL; Anderson KC; Gilleece MH; Gribben JG; Nadler LM
Br J Haematol; 2001 May; 113(2):455-60. PubMed ID: 11380416
[TBL] [Abstract][Full Text] [Related]
19. Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
Curti BD; Ochoa AC; Urba WJ; Alvord WG; Kopp WC; Powers G; Hawk C; Creekmore SP; Gause BL; Janik JE; Holmlund JT; Kremers P; Fenton RG; Miller L; Sznol M; Smith JW; Sharfman WH; Longo DL
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):296-308. PubMed ID: 8877723
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
